EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Contrasting In Vitro Activity of Nitroxoline Against Multidrug-Resistant Escherichia coli and Klebsiella pneumoniae Isolates from Outpatients

Dominik Maleš iD, Zvonimir Barišić, Darko Kero iD, Merica Carev iD

Antibiotics · 08.05.2026 · 15 (5) · 479

DOI: 10.3390/antibiotics15050479 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antibiotics, online erschienen am 08.05.2026. Verfasst von Dominik Maleš und 3 weiteren Autor:innen. Beteiligte Einrichtung: Teaching Institute for Public Health, Split-Dalmatia County, 21000 Split, Croatia. Die Arbeit nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: MIP Pharma Croatia.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Antimicrobial resistance is a major public health concern, particularly among multidrug-resistant (MDR) Enterobacterales. Nitroxoline is an older antibiotic with a unique mechanism of action that has not been widely used in recent decades. This study aimed to evaluate the in vitro activity of nitroxoline against Extended-Spectrum Beta-Lactamase (ESBL)-producing Escherichia coli (E. coli) and MDR Klebsiella pneumoniae (K. pneumoniae) isolated from urine samples of outpatients in Split-Dalmatia County, Croatia.

Methods

Nitroxoline susceptibility was assessed using disk diffusion for E. coli (n = 26) and broth microdilution for K. pneumoniae (n = 33).

Results

ESBL-producing E. coli isolates showed high susceptibility to nitroxoline, with 25 (96.2%) classified as susceptible. In contrast, K. pneumoniae isolates exhibited high minimum inhibitory concentration (MIC) values (range 16–128 mg/L; median 32 mg/L), indicating limited activity.

Conclusions

Nitroxoline demonstrated strong in vitro activity against ESBL-producing E. coli but limited activity against MDR K. pneumoniae. Interpretation of the findings for K. pneumoniae is constrained by the lack of established clinical breakpoints.

Schlagwörter

Stichwörter der Autor:innen

E. coliK. pneumoniaeantibacterial agentsantibiotic resistance screeningantimicrobial susceptibility testingmultidrug-resistant bacterianitroxoline

Autor:innen und Institutionen

  • Teaching Institute for Public Health, Split-Dalmatia County, 21000 Split, Croatia.
  • General Hospital of Šibenik-Knin County, 22000 Sibenik, Croatia.
  • Study Program of Dental Medicine, School of Medicine, University of Split, 21000 Split, Croatia.
  • University of Split, Faculty of Health Sciences, 21000 Split, Croatia.
  • School of Medicine, University of Split, 21000 Split, Croatia.
  • ESCMID Food-and-Waterborne Infections Study Group, 4051 Basel, Switzerland.

ORCID-Profile: Dominik Maleš, Darko Kero, Merica Carev

Förderung

  • MIP Pharma Croatia

Zitieren

APA

Maleš, D., Barišić, Z., Kero, D., & Carev, M. (2026). Contrasting In Vitro Activity of Nitroxoline Against Multidrug-Resistant Escherichia coli and Klebsiella pneumoniae Isolates from Outpatients. Antibiotics, 15(5), 479. https://doi.org/10.3390/antibiotics15050479

Vancouver

Maleš D, Barišić Z, Kero D, Carev M. Contrasting In Vitro Activity of Nitroxoline Against Multidrug-Resistant Escherichia coli and Klebsiella pneumoniae Isolates from Outpatients. Antibiotics. 2026;15(5):479. doi:10.3390/antibiotics15050479

BibTeX
@article{Male2026,
  author = {Maleš, Dominik and Barišić, Zvonimir and Kero, Darko and Carev, Merica},
  title = {Contrasting In Vitro Activity of Nitroxoline Against Multidrug-Resistant Escherichia coli and Klebsiella pneumoniae Isolates from Outpatients},
  journal = {Antibiotics},
  year = {2026},
  volume = {15},
  number = {5},
  pages = {479},
  doi = {10.3390/antibiotics15050479}
}
Kostenlos starten →